Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2013 | 8 | 5 | 679-684

Article title

MCP-1 and fetuin A levels in patients with PCOS and/or obesity before and after metformin treatment


Title variants

Languages of publication













Physical description


1 - 10 - 2013
18 - 9 - 2013


  • Clinic of Endocrinology, University Hospital Alexandrovska, Medical University, 1 Georgi Sofiiski blv.1431, Sofia, Bulgaria
  • Clinic of Endocrinology, University Hospital Alexandrovska, Medical University, 1 Georgi Sofiiski blv.1431, Sofia, Bulgaria
  • Central clinical laboratory, University Hospital Alexandrovska, Medical University, 1 Georgi Sofiiski blv.1431, Sofia, Bulgaria


  • [1] Ehrmann, D.A., et al., Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 1999. 22(1): p. 141–146 http://dx.doi.org/10.2337/diacare.22.1.141[Crossref]
  • [2] Legro, R.S., et al., Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab, 1999. 84(1): p. 165–169 http://dx.doi.org/10.1210/jc.84.1.165[Crossref]
  • [3] Bjorntorp, P., The android woman-a risky condition. J Intern Med, 1996. 239(2): p. 105–110 http://dx.doi.org/10.1046/j.1365-2796.1996.364690000.x[Crossref]
  • [4] Vrbikova, J., et al., Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod, 2003. 18(5): p. 980–984 http://dx.doi.org/10.1093/humrep/deg218[Crossref]
  • [5] Talbott, E., et al., Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol, 1995. 15(7): p. 821–826 http://dx.doi.org/10.1161/01.ATV.15.7.821[Crossref]
  • [6] Talbott, E., et al., Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol, 1998. 51(5): p. 415–422 http://dx.doi.org/10.1016/S0895-4356(98)00010-9[Crossref]
  • [7] Wild, R.A., P. Alaupovic, and I.J. Parker, Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol, 1992. 166(4): p. 1191–1196; discussion 1196–1997 http://dx.doi.org/10.1016/S0002-9378(11)90605-X[Crossref]
  • [8] Paradisi, G., et al., Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 2001. 103(10): p. 1410–1415 http://dx.doi.org/10.1161/01.CIR.103.10.1410[Crossref]
  • [9] Lakhani, K., et al., Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet, 2000. 356(9236): p. 1166–1167 http://dx.doi.org/10.1016/S0140-6736(00)02764-1[Crossref]
  • [10] Davila-Roman, V.G., et al., Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol, 2002. 40(2): p. 271–277 http://dx.doi.org/10.1016/S0735-1097(02)01967-8[Crossref]
  • [11] Gerszten, R.E., et al., Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med, 2000. 136(2): p. 87–92 http://dx.doi.org/10.1067/mlc.2000.108154[Crossref]
  • [12] Aiello, R.J., et al., Monocyte chemoattractant protein- 1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 1999. 19(6): p. 1518–1525 http://dx.doi.org/10.1161/01.ATV.19.6.1518[Crossref]
  • [13] Gu, L., et al., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 1998. 2(2): p. 275–281 http://dx.doi.org/10.1016/S1097-2765(00)80139-2[Crossref]
  • [14] Sartipy, P. and D.J. Loskutoff, Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA, 2003. 100(12): p. 7265–7270 http://dx.doi.org/10.1073/pnas.1133870100[Crossref]
  • [15] Hu, W.H., et al., [Monocyte chemoattractant protein- 1 and its correlation with lipoprotein in polycystic ovary syndrome]. Beijing Da Xue Xue Bao, 2006. 38(5): p. 487–491
  • [16] Gonzalez, F., et al., Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism, 2009. 58(7): p. 954–962 http://dx.doi.org/10.1016/j.metabol.2009.02.022[Crossref][WoS]
  • [17] Glintborg, D., et al., Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf), 2009. 71(5): p. 652–658 http://dx.doi.org/10.1111/j.1365-2265.2009.03523.x[Crossref][WoS]
  • [18] Auberger, P., et al., Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell, 1989. 58(4): p. 631–640 http://dx.doi.org/10.1016/0092-8674(89)90098-6[Crossref]
  • [19] Rauth, G., et al., The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem, 1992. 204(2): p. 523–529 http://dx.doi.org/10.1111/j.1432-1033.1992.tb16663.x[Crossref]
  • [20] Srinivas, P.R., et al., Serum alpha 2-HSglycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol, 1993. 7(11): p. 1445–1455 http://dx.doi.org/10.1210/me.7.11.1445[Crossref]
  • [21] Mathews, S.T., et al., Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci, 1997. 61(16): p. 1583–1592 http://dx.doi.org/10.1016/S0024-3205(97)00737-6[Crossref]
  • [22] Stefan, N., et al., Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care, 2006. 29(4): p. 853–857 http://dx.doi.org/10.2337/diacare.29.04.06.dc05-1938[Crossref]
  • [23] Mori, K., et al., Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care, 2006. 29(2): p. 468 http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1484[Crossref]
  • [24] Hennige, A.M., et al., Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One, 2008. 3(3): p. e1765 http://dx.doi.org/10.1371/journal.pone.0001765[Crossref]
  • [25] Stefan, N., et al., Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 2008. 57(10): p. 2762–2767 http://dx.doi.org/10.2337/db08-0538[Crossref]
  • [26] Roos, M., et al., Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept, 2009. 154(1–3): p. 39–43 http://dx.doi.org/10.1016/j.regpep.2008.12.001[WoS][Crossref]
  • [27] Ix, J.H., et al., Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 2006. 113(14): p. 1760–1767 http://dx.doi.org/10.1161/CIRCULATIONAHA.105.588723[Crossref]
  • [28] Weikert, C., et al., Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation, 2008. 118(24): p. 2555–2562 http://dx.doi.org/10.1161/CIRCULATIONAHA.108.814418[Crossref]
  • [29] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41–47
  • [30] Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 1995. 854: p. 1–452
  • [31] Hu, W.H., J. Qiao, and M.Z. Li, [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases]. Zhonghua Yi Xue Za Zhi, 2007. 87(11): p. 721–724
  • [32] Lindholm, A., et al., No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls. Hum Reprod, 2011. 26(6): p. 1478–1485 http://dx.doi.org/10.1093/humrep/der096[Crossref][WoS]
  • [33] Zhu, J.P., et al., [Role of testosterone in tumor necrosis factor-alpha and monocyte chemotactic protein- 1 expression in mouse macrophage RAW264.7 and its molecular mechanism]. Zhonghua Yi Xue Za Zhi, 2009. 89(35): p. 2500–2503
  • [34] Ishibashi, A., et al., Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb, 2010. 17(9): p. 925–933 http://dx.doi.org/10.5551/jat.3830[Crossref]
  • [35] Reinehr, T. and C.L. Roth, Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab, 2008. 93(11): p. 4479–4485 http://dx.doi.org/10.1210/jc.2008-1505[Crossref]
  • [36] Xu, Y., et al., Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis, 2011. 216(1): p. 180–186 http://dx.doi.org/10.1016/j.atherosclerosis.2011.01.020[Crossref]
  • [37] Mori, K., et al., Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism, 2008. 57(9): p. 1248–1252 http://dx.doi.org/10.1016/j.metabol.2008.04.019

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.